Should the left gastric artery lymph node be considered as the predictive lymph node for extra-gastric lymph node metastases?
Stomach
left gastric artery
lymph node (LN)
neoplasm
prognosis
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
4
7
2020
Statut:
ppublish
Résumé
To validate the prognostic impacts of the left gastric artery lymph node (No. 7 LN) metastasis and investigate whether the No. 7 LN metastasis should be considered as the predictive LN for extra-gastric LN metastases. Between January 2003 and December 2011, a total of 1,586 patients who underwent R0 gastrectomy were retrospected. Patients with LN metastases were divided into three groups: (I) patients with only peri-gastric LN metastases (peri-gastric group); (II) patients with peri-gastric and only No. 7 LN metastases (No. 7 group); and (III) patients with other extra-gastric LN metastases (extra-gastric group). Propensity score matching (PSM) was adopted to accurately evaluate prognoses of all patients after surgery. Of 1,586 patients, 235 (14.82%) were pathologically identified to present with the No. 7 LN metastases. Patients with the No. 7 LN metastases presented the significantly lower survival rate both before and after adjustment by pTNM stage, compared to those without the No. 7 LN metastases. Patients in the No. 7 group were identified to present the significant lower survival rate than those in the peri-gastric group, and to present the similar median overall survival (OS) to those in the extra-gastric group. In addition, patients with extra-gastric LN except No. 7 LN metastases failed to show any superiority of survival outcomes, compared with those with extra-gastric LN metastases including the No. 7 LN metastasis. The No. 7 LN metastases had the crucial survival implications. Nevertheless, the No. 7 LN failed to be considered as the predictive LN for the extra-gastric LN metastases in gastric cancer (GC).
Sections du résumé
BACKGROUND
BACKGROUND
To validate the prognostic impacts of the left gastric artery lymph node (No. 7 LN) metastasis and investigate whether the No. 7 LN metastasis should be considered as the predictive LN for extra-gastric LN metastases.
METHODS
METHODS
Between January 2003 and December 2011, a total of 1,586 patients who underwent R0 gastrectomy were retrospected. Patients with LN metastases were divided into three groups: (I) patients with only peri-gastric LN metastases (peri-gastric group); (II) patients with peri-gastric and only No. 7 LN metastases (No. 7 group); and (III) patients with other extra-gastric LN metastases (extra-gastric group). Propensity score matching (PSM) was adopted to accurately evaluate prognoses of all patients after surgery.
RESULTS
RESULTS
Of 1,586 patients, 235 (14.82%) were pathologically identified to present with the No. 7 LN metastases. Patients with the No. 7 LN metastases presented the significantly lower survival rate both before and after adjustment by pTNM stage, compared to those without the No. 7 LN metastases. Patients in the No. 7 group were identified to present the significant lower survival rate than those in the peri-gastric group, and to present the similar median overall survival (OS) to those in the extra-gastric group. In addition, patients with extra-gastric LN except No. 7 LN metastases failed to show any superiority of survival outcomes, compared with those with extra-gastric LN metastases including the No. 7 LN metastasis.
CONCLUSIONS
CONCLUSIONS
The No. 7 LN metastases had the crucial survival implications. Nevertheless, the No. 7 LN failed to be considered as the predictive LN for the extra-gastric LN metastases in gastric cancer (GC).
Identifiants
pubmed: 32617300
doi: 10.21037/atm-19-4786a
pii: atm-08-11-680
pmc: PMC7327347
doi:
Types de publication
Journal Article
Langues
eng
Pagination
680Informations de copyright
2020 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-19-4786a). The authors have no conflicts of interest to declare.
Références
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Am J Epidemiol. 2006 Jun 15;163(12):1149-56
pubmed: 16624967
Int J Clin Exp Pathol. 2015 Nov 01;8(11):14365-73
pubmed: 26823752
J Surg Oncol. 2008 Dec 1;98(7):520-5
pubmed: 18802956
Surg Clin North Am. 2000 Dec;80(6):1799-809
pubmed: 11140874
Contemp Clin Trials. 2016 Mar;47:85-92
pubmed: 26706666
Hepatogastroenterology. 2013 Sep;60(126):1513-8
pubmed: 23635507
J BUON. 2019 Mar-Apr;24(2):693-700
pubmed: 31128025
J Hepatol. 2015 Sep;63(3):643-50
pubmed: 25872167
Acta Biomater. 2018 May;72:256-265
pubmed: 29588255
Gastric Cancer. 2007;10(2):117-22
pubmed: 17577622
Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Jul;8(4):339-42
pubmed: 16167258
Eur J Surg Oncol. 2015 Mar;41(3):339-45
pubmed: 25454830
Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Oct 25;21(10):1154-1160
pubmed: 30370515
J Gastrointest Surg. 2017 Oct;21(10):1563-1570
pubmed: 28819789
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
J Gastrointest Surg. 2011 Sep;15(9):1526-31
pubmed: 21717282
Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1603-6
pubmed: 22086691
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
Gastric Cancer. 2007;10(2):87-91
pubmed: 17577617
J Natl Compr Canc Netw. 2013 May 1;11(5):531-46
pubmed: 23667204
Zhonghua Zhong Liu Za Zhi. 2008 Nov;30(11):863-5
pubmed: 19173834
J Clin Oncol. 2013 Oct 10;31(29):3704-10
pubmed: 24019550
Asian Pac J Cancer Prev. ;18(2):431-435
pubmed: 28345826
Ann Surg. 2004 Mar;239(3):383-7
pubmed: 15075656
J Surg Oncol. 2002 Mar;79(3):188-93
pubmed: 11870670
Arch Surg. 1992 Apr;127(4):392-9
pubmed: 1558490
Ann Surg. 2009 Jun;249(6):942-7
pubmed: 19474686
Surg Today. 2009;39(12):1026-31
pubmed: 19997796
Asian J Surg. 2018 Sep;41(5):462-466
pubmed: 28732676
Gastric Cancer. 2016 Jan;19(1):206-15
pubmed: 25708370
Ann Surg Oncol. 2010 May;17(5):1278-90
pubmed: 20058192
Gastric Cancer. 1998 Dec;1(1):10-24
pubmed: 11957040